.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Disease Spotlight: NMOSD

EP. 1: Temporal Evolution of MRI Lesions Identified in Different CNS Demyelinating Disorders

July 27th 2021

Complete resolution of the index T2-lesion and resolution of all T2 lesions occurred most often in patients with MOGAD rather than AQP4-IgG-NMOSD or MS.

EP. 2: Prevalence of MS and NMOSD in Indigenous Populations Dependent on Ancestry

July 24th 2021

Investigators evaluated the occurrence of multiple sclerosis and neuromyelitis optica spectrum disorder in Australian and New Zealand Indigenous populations, comparing data with ancestral data.

EP. 3: Identifying Atypical Forms, Presentations of Demyelinating Disease: Oliver Tobin, MBBCh, BAO, PhD

July 20th 2021

The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.

EP. 4: NMOSD Relapse Rates Lower During First Postpartum Trimester

July 16th 2021

These study results highlight the interest in immunosuppressive therapy taken before or during pregnancy and to reduce the risk of relapse during pregnancy and 1 year postpartum.

EP. 5: GFAP Represents Greatest Longitudinal Clinical Value Biomarker for NMOSD

July 13th 2021

Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.

EP. 6: Subcutaneous Satralizumab Gains EU Approval to Treat NMOSD

July 6th 2021

The basis for the approval was data from the phase 3 SAkuraSky and SAkuraStar studies, which combined included more than 170 patients who were treated with either satralizumab or placebo.

EP. 7: Quell TENS Device to be Used in NMOSD Study

July 6th 2021

NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.

EP. 8: Optical Coherence Tomography Angiography Helps Differentiate MS and NMOSD

July 5th 2021

Although existing research has shown structural differences between multiple sclerosis and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.

EP. 9: Leaving a Nebulous State of Care for Patients With NMOSD: Bruce Cree, MD, PhD

May 11th 2021

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.

EP. 10: Interleukin-6 Receptors in the Treatment of Neuromyelitis Optica Spectrum Disorder

April 30th 2021

NMOSD is associated with elevated levels of the pleiotropic cytokine interleukin-6, making the cytokine an apt therapeutic target.